The Clinical Analysis Of Edaravone Combined With Low Molecular Weight Heparin In The Progressive Cerebral Infarct

Object:To observe the efficence and security obout the Edaravone combined with low molecular weight heparin (LMWH) in the progressive stroke and observe the role of Edar-avone combined with LMWH,then we will explore the effects of this combined way compared with the methed used LMWH.Methods:Jilin Central Hospital in April 2008-October 2009 the incidence in 6hours-3 days,96 cases of progressive cerebral infarct patients,the progressive cerebral infarct patients were randomly divided into the edaravone injection combined with low molecular weight heparin in the treatment group (treatment group)and low molecular weight heparin in the treatment group (control group). Treatment group was treated on the basis of application of edaravone injection of 30mg intravenous normal saline 100ml,2 times per day, continuous 14 days, while low molecular weight heparin plus 5000iu,2 times per day, abdominal subcutaneous 7-10 days. The control group was treated only on the basis of low molecular weight heparin 5000iu,2 times per day, abdominal subcutaneous, continuous 7-10 days. Observation of hospitalized patients vital signs, check liver function, kidney function, blood glucose, blood lipids, line and neck vascular ultrasound, transcranial Doppler ultrasound (TCD) and head CT or MRI. Testing before and after treatment in patients with coagulation, activated partial thromboplastin time(APTT), prothrombin time(PT), thrombin time (TT), international normalized ratio (INR), plasma fibrinogen (FIB) and other coagulation, using the U.S. National Institutes of Health neurological deficit (NIHSS) score scale in the treatment, respectively before treatment and after 7 days and 14 days after treatment on the patients score, activities of daily living (Barthel index, BI) rating scale before treatment and 90 days respectively after treatment patients score.Results:(1) treatment group after treatment slightly decreased plasma fibrinogen, TT, PT, APTT slightly extended, but were within the normal range, INR not obvious abnormalities. (2) in the treatment group and control group in clinical efficacy, NIHSS score, and in the treatment of 14 days before and after treatment, BI score 90 days after treatment between the two groups had significant difference (P<0.05).Result:(1) edaravone combined with low molecular weight heparin treatment of progressive cerebral infarct with help progressive recovery of neurological function in patients with cerebral infarction, and relatively safe; (2) edaravone treatment with low molecular weight heparin in progressive cerebral infarction had no effect on blood coagulation; (3) edaravone combined with low molecular heparin in treatment of cerebral infarction compared with low molecular weight heparin therapy alone is better.